Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963677 | 0.86 | SOS1 (0.47) | ACMSDMCL1SOS1CYP1A2CYP2C19 | |
| SCHEMBL742865 | 0.84 | ACMSD (0.54) | ACMSDMCL1XDHSLC22A12SOS1 | |
| SCHEMBL3333263 | 0.78 | ESR2 (0.53) | ACMSDESR2ESR1MCL1SOS1 | |
| SCHEMBL744735 | 0.77 | KDM4E (0.48) | ACMSDESR2ESR1MCL1CYP2D6 | |
| SCHEMBL3040769 | 0.77 | HSD17B10 (0.58) | ACMSDESR2ESR1MCL1TSHR | |
| SCHEMBL2785635 | 0.77 | HSD17B10 (0.68) | ACMSDESR2ESR1MCL1CYP1A2 | |
| SCHEMBL21694758 | 0.75 | CA12 (0.53) | ACMSDESR2ESR1MCL1TSHR | |
| SCHEMBL900834 | 0.75 | HSD17B10 (0.71) | ACMSDESR2ESR1TSHRHSD17B10 | |
| SCHEMBL20695878 | 0.75 | HSD17B10 (0.66) | ACMSDESR2MCL1TSHRHSD17B10 | |
| SCHEMBL5842542 | 0.75 | ACMSD (0.55) | ACMSDSOS1CYP1A2CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | BPGBIO, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | BERG LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | BERG LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | THLIVERIS, ANDREW T. | 2022-03-31 | — | — | US | disclosed |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG PHARMA LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010132502-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132440-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132507-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-0932701-A1 | STRUCTURAL AND FUNCTIONAL CONSERVATION OF THE C. ELEGANS CLOCK GENE clk-1 | McGILL UNIVERSITY (CA) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998017823-A1 | STRUCTURAL AND FUNCTIONAL CONSERVATION OF THE C. ELEGANS CLOCK GENE $i(clk-1) | MCGILL UNIVERSITY (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | SLC25A20, NDUFB10, NDUFA10 | ACMSD 4565/4885ESR2 796/4885ESR1 1498/4885 |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | ACMSD 4497/4885ESR2 4471/4885ESR1 4050/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4450/4885ESR2 4304/4885ESR1 4588/4885 |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | NDUFA10, NDUFB10, NDUFA5 | ACMSD 3675/4885ESR2 4484/4885ESR1 4097/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | ACMSD 3722/4885ESR2 4345/4885ESR1 4180/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | ACMSD 3506/4885ESR2 640/4885ESR1 981/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | ACMSD 4565/4885ESR2 796/4885ESR1 1498/4885 |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | NDUFB10, NDUFA10, COQ8A | ACMSD 3220/4885ESR2 3956/4885ESR1 4671/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4450/4885ESR2 4304/4885ESR1 4588/4885 |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4608/4885ESR2 3523/4885ESR1 3752/4885 |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | NDUFB10, SDHB, SDHA | ACMSD 3939/4885ESR2 964/4885ESR1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.